The biopharmaceutical company Merck Serono plans to expand its oncology division. For this, the subsidiary of the pharmaceutical company Merck Darmstadt plans to cooperate with the U.S. company Mersana Therapeutics. Along one wants to develop antibody-drug conjugates of the next generation, Merck Serono says. For this, the company Mersana want to use Fleximer technology. A biodegradable polymer system (Fleximer ® ) is thereby loaded on each appropriate chemical compounds with drug and coupled via a linker to a tumor-specific antibody. The linkers are designed so that they remain stable during circulation in the blood and release the cytostatic drug at the target cell. This is a higher and better controlled drug concentration can be achieved at the tumor, is increasing the risk of side effects decrease.
Benefits of new technologies
Merck Serono is providing monoclonal antibodies and be responsible for the clinical development and commercialization of all products. For Mersana receive an upfront payment as well as performance-related milestone payments and royalties on worldwide net sales. (Db)
More about cancer and cytotoxic agents
06/25/2014 l PZ
Photo: Fotolia / Sebastian Kaulitzki
No comments:
Post a Comment